foslevodopa/foscarbidopa vs Levodopa-carbidopa intestinal gel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

foslevodopa/foscarbidopa · Vyalev

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT04380142 · Phase 3 · completed

The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).

Reported efficacy

Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)

Result source: NCT04380142

Levodopa-carbidopa intestinal gel · Duopa

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00335153 · Phase 3 · completed

This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.

Reported efficacy

Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)

Result source: NCT00357994

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfoslevodopa/​foscarbidopaLevodopa-carbidopa intestinal gel
OFF time, change-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
ON time without troublesome dyskinesia, change2.7 vs 1.0vs LD/CDwk 12 · n 47NCT043801424.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
UPDRS Part III, change—Not posted · NCT04379050-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
MDS-UPDRS Part II, change-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142—Not posted · NCT01960842

OFF time, change

foslevodopa/​foscarbidopa
-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142
Levodopa-carbidopa intestinal gel
-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381

ON time without troublesome dyskinesia, change

foslevodopa/​foscarbidopa
2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142
Levodopa-carbidopa intestinal gel
4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381

UPDRS Part III, change

foslevodopa/​foscarbidopa
—Not posted · NCT04379050
Levodopa-carbidopa intestinal gel
-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387

MDS-UPDRS Part II, change

foslevodopa/​foscarbidopa
-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142
Levodopa-carbidopa intestinal gel
—Not posted · NCT01960842
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. foslevodopa/foscarbidopa: 6 of 6 rows · Levodopa-carbidopa intestinal gel: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfoslevodopa/​foscarbidopa
Rows use multiple source trials
Levodopa-carbidopa intestinal gel
Rows use multiple source trials
OFF Time
absolute change · hours
No placebo or comparator arm
-2.4 hours @ 6wka,b,c
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more doses
-2.36 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.61 hours @ 6wkb,c
NCT01960842 · Phase 3 · registry result, not featured evidence
PDSS-2 Total
absolute change · score
-7.92 vs -2.52 LD/CD score @ 12wkb,c,d
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
-7.41 vs -8.98 Optimized Medical Treatment score @ 26wkb,c,d
NCT02549092 · Phase 3 · registry result, not featured evidence
Dropout rate
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
42.5%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
35.9%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.5%e
NCT00335153 · Phase 3
show 13 more results
5.4%
NCT00357994 · Phase 3
43.2%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
27.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
33.3%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
15.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
44.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
10.7%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
9.7%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
5.4%
NCT00660387 · Phase 3 · registry result, not featured evidence
37.5%
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Discontinued due to AEs
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
22.1%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
17.6%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4%e
NCT00335153 · Phase 3
show 13 more results
2.7%
NCT00357994 · Phase 3
18.9%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
22.7%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
11.1%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
4.4%
NCT02549092 · Phase 3 · registry result, not featured evidence
32.1%
NCT00660673 · Phase 3 · registry result, not featured evidence
3.6%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
3.2%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
2.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
—
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Serious AEs
8.1%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
25.8%ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
27.4%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24.4%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
30.5%e
NCT00335153 · Phase 3
show 13 more results
13.5%
NCT00357994 · Phase 3
66.7%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
77.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
77.8%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
20.9%
NCT02549092 · Phase 3 · registry result, not featured evidence
60.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
20.5%
NCT01736176 · Phase 3 · registry result, not featured evidence
12.9%
NCT01960842 · Phase 3 · registry result, not featured evidence
22.6%
NCT00360568 · Phase 3 · registry result, not featured evidence
13.5%
NCT00660387 · Phase 3 · registry result, not featured evidence
16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
0%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Most frequent reported AEs
infusion site erythema 27%
infusion site pain 25.7%
infusion site cellulitis 17.6%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
infusion site erythema 52%
infusion site nodule 28.7%
infusion site oedema 19.3%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
high dose
infusion site erythema 55.8%
infusion site nodule 30.1%
infusion site oedema 24.8%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
low dose
infusion site erythema 48.9%
infusion site nodule 27.5%
infusion site cellulitis 19.1%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
e
complication of device insertion 28.8%
abdominal pain 26%
insomnia 18.9%
NCT00335153 · Phase 3
show 13 more results
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00357994 · Phase 3
constipation 22.2%
depression 19.4%
device dislocation 19.4%
NCT00141518 · Phase 4 · registry result, not featured evidence
device dislocation 36.4%
excessive granulation tissue 31.8%
device related infection 27.3%
NCT00141518 · Phase 4 · registry result, not featured evidence
blood homocysteine increased 33.3%
device dislocation 27.8%
constipation 22.2%
NCT00141518 · Phase 4 · registry result, not featured evidence
stoma site pain 14%
abdominal pain 11.6%
stoma site infection 11.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
vitamin b6 decreased 27.1%
blood homocysteine increased 22.5%
postoperative wound infection 21%
NCT00660673 · Phase 3 · registry result, not featured evidence
fall 21.4%
procedural pain 10.7%
abdominal pain 7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
procedural pain 33.3%
stoma site infection 28.2%
stoma site pain 23.1%
NCT01736176 · Phase 3 · registry result, not featured evidence
incision site pain 41.9%
excessive granulation tissue 32.3%
constipation 19.4%
NCT01960842 · Phase 3 · registry result, not featured evidence
incision site erythema 29%
fall 21%
vitamin b6 decreased 21%
NCT00360568 · Phase 3 · registry result, not featured evidence
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
dyskinesia 33.3%
fall 33.3%
anaemia 16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
cold sweat 9.1%
diarrhoea 9.1%
headache 9.1%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 12 weeks versus 26 weeks.
  5. ePopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

foslevodopa/foscarbidopa

MDS-UPDRS Part II -2.65 vs -1.06 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Early Morning "Off 17% (n=47) vs 63.3% (n=60) LD/CD @ 12wk
responder rate · % of participants
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
ON Time Without Dyskinesia 3.13 vs 1.32 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDQ-39 Summary Index -6.38 vs -2.28 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
EQ-5D-5L Summary Index 0.051 vs 0.002 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Daily on Time With Troublesome Dyskinesia 0 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
0.11 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.05 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.56 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.23 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.41 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.6 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.38 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.61 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.45 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.49 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.17 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.35 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.64 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.17 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
1.74 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.99 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.6 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.81 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.72 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.93 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.92 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.65 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.79 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.74 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.69 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.71 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.08 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.43 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.77 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part I -2.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.4 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.8 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.4 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.3 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part II -2.8 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.2 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.4 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.9 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.2 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.3 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.5 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III -0.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-0.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.8 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.8 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.1 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.9 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.9 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.2 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.5 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.4 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.9 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.6 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.8 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.3 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.1 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.8 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.7 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.7 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS (Part IV -1.8 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.1 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.5 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.4 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.2 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.8 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.8 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.7 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.1 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.8 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PDSS-2 Total -5 score @ 6wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 14 more results
-7.3 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.1 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.9 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-8.2 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-7.5 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-5 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-8.4 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.6 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-7 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-7.2 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-7.1 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.5 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-8.7 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-7.5 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

+ 2 further endpoints in the CSV export.

Levodopa-carbidopa intestinal gel

AIMS Total -1.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint; n=317
NCT00335153 · Phase 3
OFF Time -4.44 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-1.3 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time With Td -0.36 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.24 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time Without Td 3.86 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
1.54 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
CGI-I 2.1 score @ 54wk
absolute value · score
No placebo or comparator arm
CGI-I at Endpoint
NCT00335153 · Phase 3
UPDRS I 0 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS II -4.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS Part III -7.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
0.6 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
UPDRS -11.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS IV -3.5 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
PDQ-39 Summary Index -6.9 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.7 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
PDQ-39 Mobility -11.2 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-2.5 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence

+ 329 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Levodopa-carbidopa intestinal gel's landscape